{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:26:22Z","timestamp":1777047982013,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>International guidelines recommend implantation of an implantable cardioverter-defibrillator (ICD) in non-ischaemic cardiomyopathy (NICM) patients with a\u00a0left ventricular ejection fraction (LVEF) below 35% despite optimal medical therapy and a\u00a0life expectancy of more than 1\u00a0year with good functional status. We propose refinement of these recommendations in patients with NICM, with careful consideration of additional risk parameters for both arrhythmic and non-arrhythmic death. These additional parameters include late gadolinium enhancement on cardiac magnetic resonance imaging and genetic testing for high-risk genetic variants to further assess arrhythmic risk, and age, comorbidities and sex for assessment of non-arrhythmic mortality risk. Moreover, several risk modifiers should be taken into account, such as concomitant arrhythmias that may affect LVEF (atrial fibrillation, premature ventricular beats) and resynchronisation therapy. Even though currently no valid cut-off values have been established, the proposed approach provides a\u00a0more careful consideration of risks that may result in withholding ICD implantation in patients with low arrhythmic risk and substantial non-arrhythmic mortality risk.<\/jats:p>","DOI":"10.1007\/s12471-024-01859-7","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T14:01:48Z","timestamp":1713448908000},"page":"190-197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of ICD eligibility in non-ischaemic cardiomyopathy patients: a\u00a0position statement by the Task Force of the Dutch Society of Cardiology"],"prefix":"10.1007","volume":"32","author":[{"given":"Anne-Lotte C. J.","family":"van der Lingen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom E.","family":"Verstraelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieselot","family":"van Erven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan G.","family":"Meeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic A.","family":"Theuns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Vernooy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur A. M.","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander H.","family":"Maass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis P.","family":"Allaart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"1859_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41572-019-0084-1","volume":"5","author":"HP Schultheiss","year":"2019","unstructured":"Schultheiss\u00a0HP, Fairweather\u00a0D, Caforio\u00a0ALP, et\u00a0al. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019;5:32.","journal-title":"Nat Rev Dis Primers"},{"issue":"42","key":"1859_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"2021","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M, et\u00a0al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J. 2021;2021:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"1859_CR3","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld\u00a0K, Tfelt-Hansen\u00a0J, de Riva\u00a0M, et\u00a0al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart\u00a0J. 2022;43:3997\u20134126.","journal-title":"Eur Heart J"},{"key":"1859_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","volume":"352","author":"GH Bardy","year":"2005","unstructured":"Bardy\u00a0GH, Lee\u00a0KL, Mark\u00a0DB, et\u00a0al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N\u00a0Engl J Med. 2005;352:225\u201337.","journal-title":"N Engl J Med"},{"key":"1859_CR5","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/01.CIR.0000012350.99718.AD","volume":"105","author":"D Bansch","year":"2002","unstructured":"Bansch\u00a0D, Antz\u00a0M, Boczor\u00a0S, et\u00a0al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453\u20138.","journal-title":"Circulation"},{"key":"1859_CR6","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa033088","volume":"350","author":"A Kadish","year":"2004","unstructured":"Kadish\u00a0A, Dyer\u00a0A, Daubert\u00a0JP, et\u00a0al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N\u00a0Engl J Med. 2004;350:2151\u20138.","journal-title":"N Engl J Med"},{"key":"1859_CR7","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/S0735-1097(03)00297-3","volume":"41","author":"SA Strickberger","year":"2003","unstructured":"Strickberger\u00a0SA, Hummel\u00a0JD, Bartlett\u00a0TG, et\u00a0al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia\u2014AMIOVIRT. J\u00a0Am Coll Cardiol. 2003;41:1707\u201312.","journal-title":"J Am Coll Cardiol"},{"key":"1859_CR8","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","volume":"375","author":"L Kober","year":"2016","unstructured":"Kober\u00a0L, Thune\u00a0JJ, Nielsen\u00a0JC, et\u00a0al. Defibrillator implantation in patients with nonischemic systolic heart failure. N\u00a0Engl J Med. 2016;375:1221\u201330.","journal-title":"N Engl J Med"},{"key":"1859_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609758","volume":"377","author":"L Shen","year":"2017","unstructured":"Shen\u00a0L, Jhund\u00a0PS, Petrie\u00a0MC, et\u00a0al. Declining risk of sudden death in heart failure. N\u00a0Engl J Med. 2017;377:41\u201351.","journal-title":"N Engl J Med"},{"key":"1859_CR10","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1161\/CIRCULATIONAHA.119.043012","volume":"140","author":"B Schrage","year":"2019","unstructured":"Schrage\u00a0B, Uijl\u00a0A, Benson\u00a0L, et\u00a0al. Association between use of primary-prevention implantable cardioverter-defibrillators and mortality in patients with heart failure: a\u00a0prospective propensity score-matched analysis from the Swedish Heart Failure Registry. Circulation. 2019;140:1530\u20139.","journal-title":"Circulation"},{"key":"1859_CR11","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1093\/eurheartj\/ehaa226","volume":"41","author":"M Zabel","year":"2020","unstructured":"Zabel\u00a0M, Willems\u00a0R, Lubinski\u00a0A, et\u00a0al. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart\u00a0J. 2020;41:3437\u201347.","journal-title":"Eur Heart J"},{"key":"1859_CR12","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/europace\/euab012","volume":"23","author":"TE Verstraelen","year":"2021","unstructured":"Verstraelen\u00a0TE, van Barreveld\u00a0M, van Dessel\u00a0P, et\u00a0al. Development and external validation of prediction models to predict implantable cardioverter-defibrillator efficacy in primary prevention of sudden cardiac death. Europace. 2021;23:887\u201397.","journal-title":"Europace"},{"key":"1859_CR13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad\u00a0F, Ferreira\u00a0JP, Pocock\u00a0SJ, et\u00a0al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a\u00a0meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396:819\u201329.","journal-title":"Lancet"},{"key":"1859_CR14","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/j.jacc.2019.02.045","volume":"73","author":"JF Huizar","year":"2019","unstructured":"Huizar\u00a0JF, Ellenbogen\u00a0KA, Tan\u00a0AY, Kaszala\u00a0K. Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review. J\u00a0Am Coll Cardiol. 2019;73:2328\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"1859_CR15","first-page":"373","volume":"2021","author":"G Hindricks","year":"2020","unstructured":"Hindricks\u00a0G, Potpara\u00a0T, Dagres\u00a0N, et\u00a0al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart\u00a0J. 2020;2021:373\u2013498.","journal-title":"Eur Heart J"},{"key":"1859_CR16","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0195-668X(03)00191-X","volume":"24","author":"AP Gorgels","year":"2003","unstructured":"Gorgels\u00a0AP, Gijsbers\u00a0C, de Vreede-Swagemakers\u00a0J, et\u00a0al. Out-of-hospital cardiac arrest\u2014the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart\u00a0J. 2003;24:1204\u20139.","journal-title":"Eur Heart J"},{"key":"1859_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1172\/JCI116540","volume":"92","author":"KP Anderson","year":"1993","unstructured":"Anderson\u00a0KP, Walker\u00a0R, Urie\u00a0P, et\u00a0al. Myocardial electrical propagation in patients with idiopathic dilated cardiomyopathy. J\u00a0Clin Invest. 1993;92:122\u201340.","journal-title":"J Clin Invest"},{"key":"1859_CR18","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jcmg.2018.03.006","volume":"11","author":"MAJ Becker","year":"2018","unstructured":"Becker\u00a0MAJ, Cornel\u00a0JH, van de Ven\u00a0PM, et\u00a0al. The prognostic value of late gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy: a\u00a0review and meta-analysis. JACC Cardiovasc Imaging. 2018;11:1274\u201384.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1859_CR19","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1161\/CIRCULATIONAHA.120.048477","volume":"143","author":"I Klem","year":"2021","unstructured":"Klem\u00a0I, Klein\u00a0M, Khan\u00a0M, et\u00a0al. Relationship of LVEF and myocardial scar to long-term mortality risk and mode of death in patients with nonischemic cardiomyopathy. Circulation. 2021;143:1343\u201358.","journal-title":"Circulation"},{"key":"1859_CR20","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1161\/CIRCULATIONAHA.116.026910","volume":"135","author":"BP Halliday","year":"2017","unstructured":"Halliday\u00a0BP, Gulati\u00a0A, Ali\u00a0A, et\u00a0al. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. 2017;135:2106\u201315.","journal-title":"Circulation"},{"key":"1859_CR21","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1016\/j.jacc.2021.04.030","volume":"77","author":"A Di Marco","year":"2021","unstructured":"Di Marco\u00a0A, Brown\u00a0PF, Bradley\u00a0J, et\u00a0al. Improved risk stratification for ventricular arrhythmias and sudden death in patients with nonischemic dilated cardiomyopathy. J\u00a0Am Coll Cardiol. 2021;77:2890\u2013905.","journal-title":"J Am Coll Cardiol"},{"key":"1859_CR22","doi-asserted-by":"crossref","unstructured":"Rahimtoola SH, Dilsizian V, Kramer CM, et\u00a0al. Chronic ischemic left ventricular dysfunction from pathophysiology to imaging and its integration into clinical practice. JACC Cardiovasc Imag. 2008;1:536\u201355.","DOI":"10.1016\/j.jcmg.2008.05.009"},{"key":"1859_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11886-019-1236-3","volume":"21","author":"M Akhtar","year":"2019","unstructured":"Akhtar\u00a0M, Elliott\u00a0PM. Risk stratification for sudden cardiac death in non-ischaemic dilated cardiomyopathy. Curr Cardiol Rep. 2019;21:155.","journal-title":"Curr Cardiol Rep"},{"key":"1859_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12471-013-0401-3","volume":"21","author":"PA van der Zwaag","year":"2013","unstructured":"van der Zwaag\u00a0PA, van Rijsingen\u00a0IA, de Ruiter\u00a0R, et\u00a0al. Recurrent and founder mutations in the Netherlands-Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy. Neth Heart\u00a0J. 2013;21:286\u201393.","journal-title":"Neth Heart J"},{"key":"1859_CR25","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1093\/eurheartj\/ehq271","volume":"31","author":"P Charron","year":"2010","unstructured":"Charron\u00a0P, Arad\u00a0M, Arbustini\u00a0E, et\u00a0al. Genetic counselling and testing in cardiomyopathies: a\u00a0position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart\u00a0J. 2010;31:2715\u201326.","journal-title":"Eur Heart J"},{"key":"1859_CR26","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.jacc.2022.06.040","volume":"80","author":"L Escobar-Lopez","year":"2022","unstructured":"Escobar-Lopez\u00a0L, Ochoa\u00a0JP, Royuela\u00a0A, et\u00a0al. Clinical risk score to predict pathogenic genotypes in patients with dilated cardiomyopathy. J\u00a0Am Coll Cardiol. 2022;80:1115\u201326.","journal-title":"J Am Coll Cardiol"},{"key":"1859_CR27","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1093\/eurheartj\/ehab294","volume":"42","author":"TE Verstraelen","year":"2021","unstructured":"Verstraelen\u00a0TE, van Lint\u00a0FHM, Bosman\u00a0LP, et\u00a0al. Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction. Eur Heart\u00a0J. 2021;42:2842\u201350.","journal-title":"Eur Heart J"},{"key":"1859_CR28","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jacc.2011.08.078","volume":"59","author":"IA van Rijsingen","year":"2012","unstructured":"van Rijsingen\u00a0IA, Arbustini\u00a0E, Elliott\u00a0PM, et\u00a0al. Risk factors for malignant ventricular arrhythmias in lamin a\/c mutation carriers a\u00a0European cohort study. J\u00a0Am Coll Cardiol. 2012;59:493\u2013500.","journal-title":"J Am Coll Cardiol"},{"key":"1859_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1161\/CIRCULATIONAHA.118.039410","volume":"140","author":"K Wahbi","year":"2019","unstructured":"Wahbi\u00a0K, Yaou\u00a0BR, Gandjbakhch\u00a0E, et\u00a0al. Development and validation of a\u00a0new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation. 2019;140:293\u2013302.","journal-title":"Circulation"},{"key":"1859_CR30","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.jacc.2016.09.927","volume":"68","author":"MF Ortiz-Genga","year":"2016","unstructured":"Ortiz-Genga\u00a0MF, Cuenca\u00a0S, Dal Ferro\u00a0M, et\u00a0al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J\u00a0Am Coll Cardiol. 2016;68:2440\u201351.","journal-title":"J Am Coll Cardiol"},{"key":"1859_CR31","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1161\/CIRCULATIONAHA.121.053521","volume":"144","author":"M Gigli","year":"2021","unstructured":"Gigli\u00a0M, Stolfo\u00a0D, Graw\u00a0SL, et\u00a0al. Phenotypic expression, natural history, and risk stratification of cardiomyopathy caused by filamin C truncating variants. Circulation. 2021;144:1600\u201311.","journal-title":"Circulation"},{"key":"1859_CR32","doi-asserted-by":"crossref","unstructured":"Authors\/Task Force m, Elliott PM, Anastasakis A, et\u00a0al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733\u201379.","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"1859_CR33","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/j.jacc.2017.03.568","volume":"69","author":"KC Bilchick","year":"2017","unstructured":"Bilchick\u00a0KC, Wang\u00a0Y, Cheng\u00a0A, et\u00a0al. Seattle Heart Failure and Proportional Risk Models predict benefit from implantable cardioverter-defibrillators. J\u00a0Am Coll Cardiol. 2017;69:2606\u201318.","journal-title":"J Am Coll Cardiol"},{"key":"1859_CR34","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1161\/CIRCULATIONAHA.117.028829","volume":"136","author":"MB Elming","year":"2017","unstructured":"Elming\u00a0MB, Nielsen\u00a0JC, Haarbo\u00a0J, et\u00a0al. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation. 2017;136:1772\u201380.","journal-title":"Circulation"},{"key":"1859_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1471-2261-14-73","volume":"14","author":"CS Lee","year":"2014","unstructured":"Lee\u00a0CS, Chien\u00a0CV, Bidwell\u00a0JT, et\u00a0al. Comorbidity profiles and inpatient outcomes during hospitalization for heart failure: an analysis of the U.S. Nationwide inpatient sample. BMC Cardiovasc Disord. 2014;14:73.","journal-title":"BMC Cardiovasc Disord"},{"key":"1859_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.amjmed.2010.08.017","volume":"124","author":"CY Wong","year":"2011","unstructured":"Wong\u00a0CY, Chaudhry\u00a0SI, Desai\u00a0MM, Krumholz\u00a0HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124:136\u201343.","journal-title":"Am J Med"},{"key":"1859_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/ejhf.685","volume":"19","author":"AC Ruwald","year":"2017","unstructured":"Ruwald\u00a0AC, Vinther\u00a0M, Gislason\u00a0GH, et\u00a0al. The impact of co-morbidity burden on appropriate implantable cardioverter defibrillator therapy and all-cause mortality: insight from Danish nationwide clinical registers. Eur J Heart Fail. 2017;19:377\u201386.","journal-title":"Eur J Heart Fail"},{"key":"1859_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jchf.2014.06.007","volume":"2","author":"BA Steinberg","year":"2014","unstructured":"Steinberg\u00a0BA, Al-Khatib\u00a0SM, Edwards\u00a0R, et\u00a0al. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a\u00a0combined analysis of 4 randomized clinical trials. JACC Heart Fail. 2014;2:623\u20139.","journal-title":"JACC Heart Fail"},{"key":"1859_CR39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/europace\/euu296","volume":"17","author":"S Barra","year":"2015","unstructured":"Barra\u00a0S, Providencia\u00a0R, Paiva\u00a0L, et\u00a0al. Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations. Europace. 2015;17:174\u201386.","journal-title":"Europace"},{"key":"1859_CR40","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","volume":"42","author":"M Glikson","year":"2021","unstructured":"Glikson\u00a0M, Nielsen\u00a0JC, Kronborg\u00a0MB, et\u00a0al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart\u00a0J. 2021;42:3427\u2013520.","journal-title":"Eur Heart J"},{"key":"1859_CR41","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/europace\/eux203","volume":"20","author":"S Barra","year":"2018","unstructured":"Barra\u00a0S, Providencia\u00a0R, Boveda\u00a0S, et\u00a0al. Do women benefit equally as men from the primary prevention implantable cardioverter-defibrillator? Europace. 2018;20:897\u2013901.","journal-title":"Europace"},{"key":"1859_CR42","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1540-8167.2008.01129.x","volume":"19","author":"AM Russo","year":"2008","unstructured":"Russo\u00a0AM, Poole\u00a0JE, Mark\u00a0DB, et\u00a0al. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. J\u00a0Cardiovasc Electrophysiol. 2008;19:720\u20134.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1859_CR43","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1002\/ehf2.13444","volume":"8","author":"ACJ van der Lingen","year":"2021","unstructured":"van der Lingen\u00a0ACJ, Theuns\u00a0D, Rijnierse\u00a0MT, et\u00a0al. Sex-specific differences in outcome and risk stratification of ventricular arrhythmias in implantable cardioverter defibrillator patients. Esc Heart Fail. 2021;8:3726\u201336.","journal-title":"Esc Heart Fail"},{"key":"1859_CR44","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cjca.2014.03.032","volume":"30","author":"R Tadros","year":"2014","unstructured":"Tadros\u00a0R, Ton\u00a0AT, Fiset\u00a0C, Nattel\u00a0S. Sex differences in cardiac electrophysiology and clinical arrhythmias: epidemiology, therapeutics, and mechanisms. Can J Cardiol. 2014;30:783\u201392.","journal-title":"Can J Cardiol"},{"key":"1859_CR45","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jacep.2019.06.007","volume":"5","author":"D de Waard","year":"2019","unstructured":"de Waard\u00a0D, Manlucu\u00a0J, Gillis\u00a0AM, et\u00a0al. Cardiac resynchronization in women: a\u00a0substudy of the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial. JACC Clin Electrophysiol. 2019;5:1036\u201344.","journal-title":"JACC Clin Electrophysiol"},{"key":"1859_CR46","doi-asserted-by":"publisher","first-page":"e006767","DOI":"10.1161\/CIRCEP.118.006767","volume":"11","author":"A Zweerink","year":"2018","unstructured":"Zweerink\u00a0A, Friedman\u00a0DJ, Klem\u00a0I, et\u00a0al. Size matters: normalization of QRS duration to left ventricular dimension improves prediction of long-term cardiac resynchronization therapy outcome. Circ Arrhythm Electrophysiol. 2018;11:e6767.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1859_CR47","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/europace\/eux235","volume":"20","author":"AM Killu","year":"2018","unstructured":"Killu\u00a0AM, Mazo\u00a0A, Grupper\u00a0A, et\u00a0al. Super-response to cardiac resynchronization therapy reduces appropriate implantable cardioverter defibrillator therapy. Europace. 2018;20:1303\u201311.","journal-title":"Europace"},{"key":"1859_CR48","doi-asserted-by":"publisher","first-page":"e008991","DOI":"10.1161\/CIRCEP.120.008991","volume":"14","author":"D Patel","year":"2021","unstructured":"Patel\u00a0D, Kumar\u00a0A, Black-Maier\u00a0E, et\u00a0al. Cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy a\u00a0systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2021;14:e8991.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1859_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12471-022-01718-3","volume":"31","author":"DA Theuns","year":"2023","unstructured":"Theuns\u00a0DA, Verstraelen\u00a0TE, van der Lingen\u00a0ACJ, et\u00a0al. Implantable defibrillator therapy and mortality in patients with non-ischaemic dilated cardiomyopathy: an updated meta-analysis and effect on Dutch clinical practice by the Task Force of the Dutch Society of Cardiology. Neth Heart\u00a0J. 2023;31:89\u201399.","journal-title":"Neth Heart J"},{"key":"1859_CR50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jchf.2021.02.013","volume":"9","author":"B Doran","year":"2021","unstructured":"Doran\u00a0B, Mei\u00a0C, Varosy\u00a0PD, et\u00a0al. The addition of a\u00a0defibrillator to resynchronization therapy decreases mortality in patients with nonischemic cardiomyopathy. JACC Heart Fail. 2021;9:439\u201349.","journal-title":"JACC Heart Fail"},{"key":"1859_CR51","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/europace\/euaa411","volume":"23","author":"W Mullens","year":"2021","unstructured":"Mullens\u00a0W, Auricchio\u00a0A, Martens\u00a0P, et\u00a0al. Optimized implementation of cardiac resynchronization therapy: a\u00a0call for action for referral and optimization of care. Europace. 2021;23:1324\u201342.","journal-title":"Europace"},{"key":"1859_CR52","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/europace\/euw445","volume":"20","author":"AH Maass","year":"2018","unstructured":"Maass\u00a0AH, Vernooy\u00a0K, Wijers\u00a0SC, et\u00a0al. Refining success of cardiac resynchronization therapy using a\u00a0simple score predicting the amount of reverse ventricular remodelling: results from the Markers and Response to CRT (MARC) study. Europace. 2018;20:e1\u2013e10.","journal-title":"Europace"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-024-01859-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-024-01859-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-024-01859-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T14:11:54Z","timestamp":1713881514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-024-01859-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1859"],"URL":"https:\/\/doi.org\/10.1007\/s12471-024-01859-7","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"30 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A.\u00a0Theuns has received research grants from Biotronik and Boston Scientific as well as consulting fees from Boston Scientific. K.\u00a0Vernooy has received research grants from Medtronic, Abbott, Biosense Webster and Philips, is listed as a\u00a0consultant for Boston Scientific, Abbott, Medtronic, Biosense Webster, Philips and Microport, is a\u00a0member of the guideline committee of the AHA\/HRS and is an associate editor of the <i>Netherlands Heart Journal<\/i>. A.A.M.\u00a0Wilde is a\u00a0member of the scientific advisory board ARMGO and Thryv Therapeutics. C.P.\u00a0Allaart is president of the Netherlands Heart Rhythm Association, has received institutional research grants from Abbott, Biotronik and Medtronic as well as speaker fees from Abbott and Medtronic, and is an associate editor of the <i>Netherlands Heart Journal<\/i>. A.-L.C.J.\u00a0van der Lingen, T.E.\u00a0Verstraelen, L.\u00a0van Erven, J.G.\u00a0Meeder and A.H.\u00a0Maass declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}